Načítá se...
ACE inhibitors, angiotensin receptor blockers and endothelial injury in COVID‐19
BACKGROUND: COVID‐19 is caused by the coronavirus SARS‐CoV‐2, which uses angiotensin‐converting enzyme 2 (ACE‐2) as a receptor for cellular entry. It is theorized that ACE inhibitors (ACE‐Is) or angiotensin receptor blockers (ARBs) may increase vulnerability to SARS‐CoV‐2 by upregulating ACE‐2 expre...
Uloženo v:
| Vydáno v: | J Intern Med |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7753609/ https://ncbi.nlm.nih.gov/pubmed/33210357 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/joim.13202 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|